Yoshiro Maru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoshiro Maru has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Masabumi Shibuya
5 shared publicationsA Okada
1 shared publicationEtienne Bergmann
1 shared publication- Frédéric Coin
IGBMC
1 shared publication Hiroshige Hirosawa
1 shared publicationJean-Marc Egly
1 shared publication
Latest Publications
- 1 November 2001
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 483 (1-2) , 83-88
TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome
- 1 November 2001
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 483 (1-2) , 83-88
TFIIH functions are altered by the P210BCR-ABL oncoprotein produced on the Philadelphia chromosome
- 1 September 2001
- Published by Elsevier in Leukemia Research
- Vol. 25 (9) , 821-825
Inhibition of protein kinase C δ has negative effect on anchorage-independent growth of BCR-ABL-transformed Rat1 cells
- 1 September 2001
- Published by Elsevier in Leukemia Research
- Vol. 25 (9) , 821-825
Inhibition of protein kinase C δ has negative effect on anchorage-independent growth of BCR-ABL-transformed Rat1 cells
- 14 August 2001
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1540 (2) , 147-153
The tubulogenic activity associated with an activated form of Flt-1 kinase is dependent on focal adhesion kinase
- 14 August 2001
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1540 (2) , 147-153
The tubulogenic activity associated with an activated form of Flt-1 kinase is dependent on focal adhesion kinase
- 1 April 2001
- Published by Springer Nature in International Journal of Hematology
- Vol. 73 (3) , 308-322
Molecular Biology of Chronic Myeloid Leukemia
Multistep carcinogenesis is exemplified by chronic myeloid leukemia with clinical manifestation consisting of a chronic phase and blast crisis. Pathological generation of BCR-ABL (breakpoint cluster region-Abelson) results in growth promotion, differentiation, resistance to apoptosis, and defect in DNA repair in targeted blood cells. Domains in BCR and ABL sequences work in concert to elicit a variety of leukemogenic signals including Ras, STAT5 (signal transducer and activator of transcription-5), Myc, cyclin D1, PI3 (phosphatidylinositol 3-kinase), RIN1 (Ras interaction/interference), and activation of actin cytoskeleton. However, the mechanism of differentiation of transformed cells is poorly understood. A mutator phenotype of BCR-ABL could explain the transformation to blast crisis.The aim of this review is to integrate molecular and biological information on BCR, ABL, and BCR-ABL and to focus on how signaling from those molecules mirrors the biological phenotypes of chronic myeloid leukemia.
- 1 April 2001
- Published by Springer Nature in International Journal of Hematology
- Vol. 73 (3) , 308-322
Molecular Biology of Chronic Myeloid Leukemia
Multistep carcinogenesis is exemplified by chronic myeloid leukemia with clinical manifestation consisting of a chronic phase and blast crisis. Pathological generation of BCR-ABL (breakpoint cluster region-Abelson) results in growth promotion, differentiation, resistance to apoptosis, and defect in DNA repair in targeted blood cells. Domains in BCR and ABL sequences work in concert to elicit a variety of leukemogenic signals including Ras, STAT5 (signal transducer and activator of transcription-5), Myc, cyclin D1, PI3 (phosphatidylinositol 3-kinase), RIN1 (Ras interaction/interference), and activation of actin cytoskeleton. However, the mechanism of differentiation of transformed cells is poorly understood. A mutator phenotype of BCR-ABL could explain the transformation to blast crisis.The aim of this review is to integrate molecular and biological information on BCR, ABL, and BCR-ABL and to focus on how signaling from those molecules mirrors the biological phenotypes of chronic myeloid leukemia.
- 1 February 2001
- Vol. 61 (3) , 1207-13
Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.
Vascular endothelial growth factor (VEGF) and its two receptors, Fms-like tyrosine kinase 1 (Flt-1) (VEGFR-1) and KDR/Flk-1 (VEGFR-2), have been demonstrated to be an essential regulatory system for blood vessel formation in mammals. KDR is a major positive signal transducer for angiogenesis through its strong tyrosine kinase activity. Flt-1 has a unique biochemical activity, 10-fold higher affinity to VEGF, whereas much weaker tyrosine kinase activity compared with KDR. Recently, we and others have shown that Flt-1 has a negative regulatory function for physiological angiogenesis in the embryo, possibly with its strong VEGF-trapping activity. However, it is still open to question whether the tyrosine kinase of Flt-1 has any positive role in angiogenesis at adult stages. In this study, we examined whether Flt-1+ could be a positive signal transducer under certain pathological conditions, such as angiogenesis with tumors overexpressing a Flt-1-specific, VEGF-related ligand. Our results show clearly that murine Lewis lung carcinoma cells overexpressing placenta growth factor-2, an Flt-1-specific ligand, grew in wild-type mice much faster than in Flt-1 tyrosine kinase domain-deficient mice. Blood vessel formation in tumor tissue was higher in wild-type mice than in Flt-1 tyrosine kinase-deficient mice. On the other hand, the same carcinoma cells overexpressing VEGF showed no clear difference in the tumor growth rate between these two genotypes of mice. These results indicate that Flt-1 is a positive regulator using its tyrosine kinase under pathological conditions when the Flt-1-specific ligand is abnormally highly expressed. Thus, Flt-1 has a dual function in angiogenesis, acting in a positive or negative manner in different biological conditions.
- 1 February 2001
- Vol. 61 (3) , 1207-13
Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.
Vascular endothelial growth factor (VEGF) and its two receptors, Fms-like tyrosine kinase 1 (Flt-1) (VEGFR-1) and KDR/Flk-1 (VEGFR-2), have been demonstrated to be an essential regulatory system for blood vessel formation in mammals. KDR is a major positive signal transducer for angiogenesis through its strong tyrosine kinase activity. Flt-1 has a unique biochemical activity, 10-fold higher affinity to VEGF, whereas much weaker tyrosine kinase activity compared with KDR. Recently, we and others have shown that Flt-1 has a negative regulatory function for physiological angiogenesis in the embryo, possibly with its strong VEGF-trapping activity. However, it is still open to question whether the tyrosine kinase of Flt-1 has any positive role in angiogenesis at adult stages. In this study, we examined whether Flt-1+ could be a positive signal transducer under certain pathological conditions, such as angiogenesis with tumors overexpressing a Flt-1-specific, VEGF-related ligand. Our results show clearly that murine Lewis lung carcinoma cells overexpressing placenta growth factor-2, an Flt-1-specific ligand, grew in wild-type mice much faster than in Flt-1 tyrosine kinase domain-deficient mice. Blood vessel formation in tumor tissue was higher in wild-type mice than in Flt-1 tyrosine kinase-deficient mice. On the other hand, the same carcinoma cells overexpressing VEGF showed no clear difference in the tumor growth rate between these two genotypes of mice. These results indicate that Flt-1 is a positive regulator using its tyrosine kinase under pathological conditions when the Flt-1-specific ligand is abnormally highly expressed. Thus, Flt-1 has a dual function in angiogenesis, acting in a positive or negative manner in different biological conditions.
- 1 February 2000
- Published by Elsevier in European Journal of Cell Biology
- Vol. 79 (2) , 130-143
An oncogenic form of the Flt-1 kinase has a tubulogenic potential in a sinusoidal endothelial cell line
- 1 February 2000
- Published by Elsevier in European Journal of Cell Biology
- Vol. 79 (2) , 130-143
An oncogenic form of the Flt-1 kinase has a tubulogenic potential in a sinusoidal endothelial cell line
- 1 July 1999
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 260 (2) , 309-312
BCR Binds to the Xeroderma Pigmentosum Group B Protein
- 1 July 1999
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 260 (2) , 309-312
BCR Binds to the Xeroderma Pigmentosum Group B Protein
- 5 January 1999
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (1) , 203-207
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein
The previously uncharacterized CDC24 homology domain of BCR, which is missing in the P185 BCR-ABL oncogene of Philadelphia chromosome (Ph1)-positive acute lymphocytic leukemia but is retained in P210 BCR-ABL of chronic myelogeneous leukemia, was found to bind to the xeroderma pigmentosum group B protein (XPB). The binding appeared to be required for XPB to be tyrosine-phosphorylated by BCR-ABL. The interaction not only reduced both the ATPase and the helicase activities of XPB purified in the baculovirus system but also impaired XPB-mediated cross-complementation of the repair deficiency in rodent UV-sensitive mutants of group 3. The persistent dysfunction of XPB may in part underlie genomic instability in blastic crisis.
- 5 January 1999
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (1) , 203-207
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein
The previously uncharacterized CDC24 homology domain of BCR, which is missing in the P185 BCR-ABL oncogene of Philadelphia chromosome (Ph1)-positive acute lymphocytic leukemia but is retained in P210 BCR-ABL of chronic myelogeneous leukemia, was found to bind to the xeroderma pigmentosum group B protein (XPB). The binding appeared to be required for XPB to be tyrosine-phosphorylated by BCR-ABL. The interaction not only reduced both the ATPase and the helicase activities of XPB purified in the baculovirus system but also impaired XPB-mediated cross-complementation of the repair deficiency in rodent UV-sensitive mutants of group 3. The persistent dysfunction of XPB may in part underlie genomic instability in blastic crisis.